Taken together, it seems that the absence of SRPX2 legitimate transcriptional activity, together with the SRPX2 strong intron retention process, can serve as a unified molecular signature for melanoma identification and its distinction from non-melanoma (BCC and SCC) skin cancers. Here, SRPX2 is linked to melanoma.